Strand Life Sciences announces launch of prenatal genomic diagnostics portfolio
India, April 24 -- Bengaluru-basedStrand Life Sciences has announced the launch of its prenatal screening and diagnostics portfolio with two breakthrough developments- CNSeq (sequencing based identification of aneuploidies and copy number variations) and MaatriSeq (Non-Invasive Prenatal Screening).
CNSeq brings the latest Next Generation Sequencing technology to an important prenatal test marking a significant leap forward in prenatal diagnostics. Leveraging proprietary software, CNSeq delivers unmatched precision in identifying Copy Number Variations (CNVs), outperforming traditional cytogenetic and molecular techniques.
On the other hand, MaatriSeq is the first Non-Invasive Prenatal Screening (NIPS) solution validated on the latest hi...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.